Ligand Pharma (LGND) Tops Q2 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $317.33 -0.45%
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.37, $0.42 better than the analyst estimate of $1.95. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $62.93 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hershey (HSY) PT Lowered to $194 at Goldman Sachs
- Roblox Corp. (RBLX) PT Lowered to $55 at Goldman Sachs
- First Northern Community Bancorp (FNRN) Tops Q3 EPS by 38c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
